Three-year follow-up of galantamine therapy for Alzheimer's disease: Efficacy and tolerability in open-label extension studies

Three-year follow-up of galantamine therapy for Alzheimer's disease: Efficacy and tolerability in open-label extension studies

Bibliographic Details
Main Authors:	Wilcock, G, Truyen, L
Format:	Journal article
Published:	2002

Similar Items

Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data
by: Wilcock, G, et al.
Published: (2002)

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
by: Pirttilä, T, et al.
Published: (2004)

Galantamine in Alzheimer's disease.
by: Razay, G, et al.
Published: (2008)

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
by: Wilcock, G, et al.
Published: (2003)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
by: Wilcock, G, et al.
Published: (2000)

Safety and efficacy of galantamine in subjects with mild cognitive impairment.
by: Winblad, B, et al.
Published: (2008)

The beneficial effects of galantamine on caregiver time in Alzheimer's disease
by: Sano, M, et al.
Published: (2003)

The effects of galantamine treatment on caregiver time in Alzheimer's disease.
by: Sano, M, et al.
Published: (2003)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial (vol 321, pg 1445, 2000)
by: Wilcock, G
Published: (2001)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9) (1445-1449))
by: Wilcock, G
Published: (2001)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))
by: Wilcock, G
Published: (2001)

Galantamine vs donepezil in the treatment of Alzheimer's disease.
by: Goldlist, B, et al.
Published: (2003)

A long-term comparison of galantamine and donepezil in the treatment of moderate-to-severe Alzheimer's disease: An intent-to-treat analysis
by: Wilcock, G, et al.
Published: (2003)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
by: Yi-Ting Lin, et al.
Published: (2019-05-01)

Effect of galantamine on time to residential or nursing home admission
by: Feldman, H, et al.
Published: (2004)

Can we predict the response to Galantamine in Alzheimer`s disease patients?
by: Carmen Gavan, et al.
Published: (2015-09-01)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
by: Ben Seltzer
Published: (2009-12-01)

Design and development of galantamine hydrobromide transdermal patch for treatment of alzheimer’s disease
by: Woo, Fong Yen
Published: (2015)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
by: Yasir Hasan Siddique, et al.
Published: (2022-01-01)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
by: E Loveman, et al.
Published: (2006-01-01)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
by: Hager K, et al.
Published: (2014-10-01)

Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis.
by: Joffres, C, et al.
Published: (2003)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
by: Dan-Dan Li, et al.
Published: (2019-05-01)

Hierarchical adhesive hydrogel microparticles with galantamine hydrobromide encapsulation for the treatment of Alzheimer’s disease
by: Huijuan Zhou, et al.
Published: (2024-10-01)

Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study
by: Hossein Pakdaman, et al.
Published: (2018-04-01)

Galantamine ameliorates experimental pancreatitis
by: Dane A. Thompson, et al.
Published: (2023-10-01)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
by: Mohd Adnan, et al.
Published: (2023-09-01)

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
by: Schmidt Luisa, et al.
Published: (2010-04-01)

Correction: Galantamine ameliorates experimental pancreatitis
by: Dane A. Thompson, et al.
Published: (2024-04-01)

Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine
by: Yukio Ago, et al.
Published: (2011-01-01)

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
by: J. Bryant, et al.
Published: (2001-01-01)

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study
by: Ian Pavord, et al.
Published: (2024-12-01)

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
by: Damon Bass, et al.
Published: (2022-04-01)

Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.
by: Soumee Bhattacharya, et al.
Published: (2014-01-01)

Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy
by: Dilyana Georgieva, et al.
Published: (2023-03-01)

Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy
by: Stavroula G. Nanaki, et al.
Published: (2020-03-01)

Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
by: Manickam Rajkumar, et al.
Published: (2022-01-01)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
by: Woo FY, et al.
Published: (2015-06-01)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
by: Willian O Castillo, et al.
Published: (2017-01-01)

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
by: Lilly Mary L, et al.
Published: (2005-01-01)